Objective-To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction.
Abstract
Objective-To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction.
Design-Patients were randomly allocated to receive either 15 x 10' IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and subsequently at intervals up to 30 months; plasma samples were assayed for streptokinase resistance titre (functional assay) and streptokinase binding by IgG (microradioimmunoassay). Setting-Cardiology department in a general hospital.
Patients-128 consecutive eligible patients. Samples were collected for up to one year according to a prospective design: a subsection of 47 patients was selected for intensive study over the first 14 days. After one year, all available patients (67) were sampled on one further occasion.
Results-Antibody responses to streptokinase and anistreplase were similar. Streptokinase resistance titres exceeded pretreatment concentrations five days after dosing, and values peaked at 14 days. By 12 
Results

SK RESISTANCE TITRE
Early serial changes (one to 14 days) were studied in detail in a subgroup of 47 patients. The response was similar whether patients were treated with SK or anistreplase, and baseline (pretreatment) values were consistently exceeded by five days after dosing (fig 1) . Figure 2 shows results for all patients, monitored up to 30 months. Measurements up to 12 months are serial analyses in the same patients (although a maximum of only 84 out of a possible 115 samples were collected in the prospectively designed study). By contrast, each patient was only sampled once over the period 12-30 months; that is, different patients appear in the groups collated at 18, 24, and 30 months and therefore groups are smaller at these times. Sampling times for the points within the period 12-30 months represent ranges: the total ranges are specified in the table.
Changes in SK resistance titre were similar for SK and anistreplase throughout the period of follow up (fig 2) . Baseline (pretreatment) values however were significantly higher in the group of patients assigned to treatment with anistreplase (50 v 20 IU/ml, p < 0 05). IgG (fig 3) is not accompanied by a similar decline in SK resistance titre (fig 1) . Figure 4 showed results for all patients monitored up to 30 months: changes in anti-SK IgG were similar for SK and anistreplase throughout the period of follow up. It is noteworthy that baseline values are not higher in the patients assigned to anistreplase, unlike the situation with SK resistance titre (fig 2) .
In agreement with the changes in SK resistance titre, peak values of anti-SK IgG were attained 14 days after dosing (150 fold rise in median). The subsequent decline in anti-SK IgG, however, seemed somewhat slower than the decline in SK resistance titre: 48% of individual anti-SK IgG values returned to within the normal range by 12 months after dosing (14% at six months, 61% at 18 months, 65% at 24 months, and 89% at 30 months).
Discussion
We have shown already that the range of concentrations of anti-SK antibodies found in AMI populations before first treatmentwhether measured specifically as IgG or as the functional SK resistance titre-does not usually influence the thrombolytic efficacy of SK and anistreplase or the incidence of side effects.28 The concentration of antibody is usually low by comparison with the concentration required to bind all SK or anistreplase used,29 0 and the inhibition of lysis is much less than the extent of binding. 29 We have now shown that high values of neutralising antibody are rapidly induced after dosing with anistreplase and SK and the two agents seem to be indistinguishable. When measured in terms of the functional SK resistance titre, the present results confirm and extend previous findings, showing that most values return to within the normal range by six to 12 months. Extrapolating from group SK resistance titres to calculate how much of a second dose of SK might be neutralised, opinions on the possibility of readministration have varied from three months to greater than six months.' 34 5 Our results suggest that much of a second standard dose (1 5 x 106 IU) of SK might be neutralised up to six months after the first dose but not at 12 months.
Our assay for specific anti-SK IgG is novel and these are the first results to define the rate of induction and decline after dosing with SK or anistreplase. The incremental change from baseline to two months appears similar to the preliminary results on SK published recently for an enzyme linked immunosorbent assay (ELISA) method." The initial production of IgG, however, appeared to be more rapid when measured by ELISA than by radioimmunoassay in the present or a previous study.2 At the very high concentrations reached in the first few months, anti-SK IgG is a major contributor to the functional SK resistance titre. The fall in IgG during the first four days after treatment is not accompanied, however, by a reduction in SK resistance titre presumably because the fibrinolytic assay reflects the changes in fibrinogen, plasminogen, and ox2-antiplasmin. The significantly higher baseline SK resistance titre in anistreplase treated patients and the poor correlation between changes in anti-SK IgG and SK resistance from three months onwards may also reflect contributions other than anti-SK IgG, possibly a2 antiplasmin.
Anti-SK IgG antibodies have occasionally been implicated in adverse reactions after thrombolytic therapy with SK." In view of the very low incidence of severe allergic-type reactions in the large mortality trials of anistreplase'2 and SK,1314 however, it is not clear whether an appreciable risk is incurred when IgG is higher. The concentrations of anti-SK IgG in the few patients in our study who showed an allergic-like response7 were not appreciably different from the concentrations in patients without a response.
There are few publications on the size of the increment in clinically diagnosed allergic-type reactions in response to other antigens when IgG is raised. Work on dextrans indicates that most reactions seen when the IgG antibody titre increases beyond a range of 10 fold from the normal median are likely to be mild (grade I); more severe reactions require a much higher antibody concentration. '5 Furthermore, although serious allergic type reactions are mediated by the complement pathway, complement is also lysed by plasmin in response to plasminogen activators such as alteplase. '6 Therefore, complement activation and any contingent leucocyte attraction may occur regardless of the concentrations of anti-SK IgG.
In conclusion, we have defined the induction of neutralising antibodies to SK and anistreplase in AMI patients with the standard functional assay of SK resistance titre.' 3 4 'The responses to anistreplase and SK are similar.
Because of the increased likelihood of resistance due to anti-SK antibody, SK, and anistreplase may not be effective if administered more than five days after earlier SK or anistreplase particularly between five days and 12 months, and increased anti-SK antibody concentrations may increase the risk of allergictype reactions.
